Dermatology, Venereology and Andrology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Dermatol Surg. 2022 Aug 1;48(8):843-848. doi: 10.1097/DSS.0000000000003490. Epub 2022 Jun 17.
Facial hyperhidrosis (HH), a common problem with both cosmetic and psychological impact, interferes with quality of life. Wide range of treatment options is available for HH. Finding the most effective and yet a safe, tolerable option is the main target.
To evaluate and compare clinical efficacy, safety, and tolerability of topical 2% glycopyrrolate versus intradermal Botulinum toxin A injection in facial HH treatment.
Twenty-four patients with primary facial HH were randomly divided into 2 equal groups: Group A included patients treated by intradermal Botulinum toxin A injection and Group B included patients treated by topical glycopyrrolate gel 2%. Starch iodine test was performed before and after treatment to assess response, along with Hyperhidrosis Disease Severity Scale, Dermatology Life Quality Index (DLQI), and patient satisfaction.
Both modalities showed complete response in 75% of cases with a longer duration of action in botulinum toxin group up to 6 months. Side effects were minor and temporary. Both Hyperhidrosis Disease Severity Scale and DLQI showed statistically significant improvement after treatment.
Topical glycopyrrolate 2% showed comparable results to Botulinum toxin A in facial HH treatment with faster onset but shorter duration of action.
面部多汗症（HH）是一种常见的问题，具有美容和心理影响，干扰生活质量。有广泛的治疗选择可供HH。找到最有效且安全、耐受的选择是主要目标。
评估和比较 2%的吡咯烷酮与肉毒杆菌毒素 A 皮内注射治疗面部 HH 的临床疗效、安全性和耐受性。
24 例原发性面部 HH 患者随机分为 2 组：A 组患者接受肉毒杆菌毒素 A 皮内注射治疗，B 组患者接受 2%吡咯烷酮凝胶治疗。治疗前后进行淀粉碘试验以评估反应，同时评估多汗症严重程度量表、皮肤病生活质量指数（DLQI）和患者满意度。
两种方法均使 75%的病例完全缓解，肉毒杆菌毒素组的作用持续时间更长，可达 6 个月。副作用轻微且短暂。多汗症严重程度量表和 DLQI 均显示治疗后有统计学意义的改善。
2%的吡咯烷酮与肉毒杆菌毒素 A 在面部 HH 治疗中具有相当的疗效，起效更快，但作用持续时间更短。
